Cargando…

Lack of pharmacokinetic interaction between the HIV‐1 maturation inhibitor GSK3640254 and combination oral contraceptives in healthy women

AIMS: GSK3640254 is a next‐generation maturation inhibitor likely to be coadministered with combined oral contraceptives in HIV‐positive women. METHODS: This phase I, open‐label, 1‐way study assessed pharmacokinetic and pharmacodynamic interactions of GSK3640254 200 mg and ethinyl oestradiol 0.03 mg...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pene Dumitrescu, Teodora, Greene, Thomas J., Joshi, Samit R., Xu, Jianfeng, Johnson, Mark, Halliday, Fiona, Butcher, Laurie, Zimmerman, Eric, Webster, Lindsey, Pham, Theresa T., Lataillade, Max, Min, Sherene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9291532/ https://www.ncbi.nlm.nih.gov/pubmed/34427938 http://dx.doi.org/10.1111/bcp.15051

Ejemplares similares

Phase I evaluation of pharmacokinetics and tolerability of the HIV‐1 maturation inhibitor GSK3640254 and dolutegravir in healthy adults
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

A Phase I Evaluation of the Pharmacokinetics and Tolerability of the HIV-1 Maturation Inhibitor GSK3640254 and Tenofovir Alafenamide/Emtricitabine in Healthy Participants
por: Pene Dumitrescu, Teodora, et al.
Publicado: (2021)

Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants
por: Johnson, Mark, et al.
Publicado: (2022)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
por: Joshi, Samit R., et al.
Publicado: (2020)

Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254( )
por: Spinner, Christoph D, et al.
Publicado: (2022)

Effects of the HIV‐1 maturation inhibitor GSK3640254 on QT interval in healthy participants
por: Zhang, Ying, et al.
Publicado: (2023)

GSK3640254 Is a Novel HIV-1 Maturation Inhibitor with an Optimized Virology Profile
por: Dicker, Ira, et al.
Publicado: (2022)

Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial
por: Morales-Ramirez, Javier, et al.
Publicado: (2018)

Integrating In Vitro Biopharmaceutics into Physiologically Based Biopharmaceutic Model (PBBM) to Predict Food Effect of BCS IV Zwitterionic Drug (GSK3640254)
por: Stamatopoulos, Konstantinos, et al.
Publicado: (2023)

Resistance profile of the HIV-1 maturation inhibitor GSK3532795 in vitro and in a clinical study
por: Dicker, Ira, et al.
Publicado: (2019)

Population Pharmacokinetics and Pharmacodynamics Modelling of Dilmapimod in Severe Trauma Subjects at Risk for Acute Respiratory Distress Syndrome
por: Yang, Shuying, et al.
Publicado: (2016)

Contraception for midlife women: lack of information? Lack of interest? Lack of investment?
por: Woods, Nancy Fugate, et al.
Publicado: (2017)

The Second-Generation Maturation Inhibitor GSK3532795 Maintains Potent Activity Toward HIV Protease Inhibitor–Resistant Clinical Isolates
por: Ray, Neelanjana, et al.
Publicado: (2017)

Pharmacometrics: Focus on the Patient
por: Dumitrescu, T Pene, et al.
Publicado: (2015)

Clinical evidence for a lack of cross-resistance between temsavir and ibalizumab or maraviroc
por: Rose, Ronald, et al.
Publicado: (2022)

A phase I, first‐in‐human study investigating the safety, tolerability, and pharmacokinetics of the maturation inhibitor GSK3739937
por: Benn, Paul D., et al.
Publicado: (2023)

Contraceptive considerations for breastfeeding women within Jewish law
por: Chertok, Ilana R, et al.
Publicado: (2007)

A qualitative analysis of Medicaid beneficiaries perceptions of prenatal and immediate postpartum contraception counseling
por: Yates, Lindsey, et al.
Publicado: (2022)

Bioequivalence and Food Effect Assessment of 2 Fixed‐Dose Combination Formulations of Dolutegravir and Lamivudine
por: Dumitrescu, Teodora Pene, et al.
Publicado: (2019)

Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir
por: Lataillade, Max, et al.
Publicado: (2018)

Lack of Matrilin-2 Favors Liver Tumor Development via Erk1/2 and GSK-3β Pathways In Vivo
por: Fullár, Alexandra, et al.
Publicado: (2014)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
por: Smith, Robert A., et al.
Publicado: (2023)

Novel Reporter Alleles of GSK-3α and GSK-3β
por: Barrell, William B., et al.
Publicado: (2012)

HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, Hck
por: Pene-Dumitrescu, Teodora, et al.
Publicado: (2012)

The safety, tolerability, and pharmacokinetic profile of GSK2838232, a novel 2nd generation HIV maturation inhibitor, as assessed in healthy subjects
por: Johnson, Mark, et al.
Publicado: (2018)

Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol‐containing oral contraceptive in healthy adult women
por: Trezza, Christine, et al.
Publicado: (2017)

Lack of Effect of Cenerimod, a Selective S1P(1) Receptor Modulator, on the Pharmacokinetics of a Combined Oral Contraceptive
por: Juif, Pierre-Eric, et al.
Publicado: (2022)

Measuring experiences and concerns surrounding contraceptive induced side-effects in a nationally representative sample of contraceptive users: Evidence from PMA Ethiopia
por: Zimmerman, Linnea A., et al.
Publicado: (2022)

Biomarkers and Diagnostics Will Play Essential Roles in Advancing Innovative Contraception
por: Lindsey, Christopher C., et al.
Publicado: (2022)

Antiviral Activity, Safety, and Exposure–Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase 2a Randomized, Dose-Ranging, Controlled Trial (AI468002)
por: Hwang, Carey, et al.
Publicado: (2017)

Advances in contraception: vaginal contraceptive rings
por: Al-Haddad, Sara, et al.
Publicado: (2023)

Men’s attitudes on gender equality and their contraceptive use in Uttar Pradesh India
por: Mishra, Anurag, et al.
Publicado: (2014)

Structural Plasticity of Dendritic Spines Requires GSK3α and GSK3β
por: Cymerman, Iwona A., et al.
Publicado: (2015)

GSK3α and GSK3β Phosphorylate Arc and Regulate its Degradation
por: Gozdz, Agata, et al.
Publicado: (2017)

EPS8L3 promotes pancreatic cancer proliferation and metastasis by activating GSK3B
por: Fan, Zun, et al.
Publicado: (2023)

Contraception
Publicado: (1976)

Contraception
por: McMahon, Sharon, et al.
Publicado: (2004)

Contraception
Publicado: (1924)

GSK-3 in Neurodegenerative Diseases
por: Lei, Peng, et al.
Publicado: (2011)

Non-Contraceptive Benefits of Oral Hormonal Contraceptives
por: Schindler, Adolf E
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_03hp0ck1k90ft3e3i53sdtmau9